New Drugs Treat Rare Heart Disease Caused by Transthyretin-Mediated Amyloidosis
The Food and Drug Administration (FDA) has approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) for the treatment of cardiomyopathy caused by transthyretin-mediated amyloidosis in adults. These are the first FDA-approved drug treatments for this rare genetic disorder.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research
More News: Amyloidosis | Cardiology | Cardiomyopathy | Food and Drug Administration (FDA) | Genetics | Heart | Heart Disease | Nursing